New bioinformatic workflow advances analysis capabilities
for whole exome assessment and interpretation
BOSTON and LAUSANNE, Switzerland, Nov. 1, 2021 /PRNewswire/ -- SOPHiA GENETICS
SA (Nasdaq: SOPH), the creator of a global data pooling and
knowledge sharing platform that advances data-driven
medicine, announced today they have extended their SOPHiA
DDM™ Universal Whole Exome analytical capabilities to
include industry leading exome SureSelect Human All Exon v8 by
Agilent. The new SOPHiA GENETICS pipeline is tailored to the unique
features of this product to maximize support for Agilent customers
in automating their next generation sequencing (NGS) workflows with
enhanced, cutting-edge interpretation tools for germline and cancer
applications.
SOPHiA GENETICS' Universal Whole Exome solution delivers a
streamlined end-to-end workflow, from sample to variant report, to
advance rare and inherited disease research studies using any exome
product. The new SOPHiA DDM™ for
SureSelect Human All Exon v8 is a fully integrated, FASTQ-to-report
bioinformatic workflow for whole exome analysis
and interpretation.
The SOPHiA DDM™ for SureSelect Human All
Exon v8 offers:
- A complete analytical workflow for reduced turnaround time
- Multiple types of variants detection
- Tailored analytics for Agilent-specific sample data
- Uniform and comprehensive gene coverage
- Knowledge sharing across the SOPHiA Community
- Improved tertiary analytics
- An enhanced user experience
The SOPHiA DDM™ platform supports multiple
commercially available exome panels with tailored pipelines and
robust analytics for each, enabling uniform coverage of the target
region and a streamlined workflow to reduce overall turnaround time
and accelerate rare disease characterization.
To learn more about how SOPHiA GENETICS data-driven insights are
improving diagnosis, treatment, and drug development for patients
and the larger medical community, visit www.sophiagenetics.com.
About SOPHiA GENETICS:
SOPHiA GENETICS is a healthcare
technology company dedicated to establishing the practice of
data-driven medicine as the standard of care and for life sciences
research. It is the creator of the SOPHiA DDM™ Platform,
a cloud-based SaaS platform capable of analyzing data and
generating insights from complex multimodal data sets and different
diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by more
than 780 hospital, laboratory, and biopharma institutions
globally.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information included in this press release is about products that
may or may not be available in different countries and, if
applicable, may or may not have received approval or market
clearance by a governmental regulatory body for different
indications for use. Please contact
support@sophiagenetics.com to obtain the
appropriate product information for your country of residence.
More info: SOPHiAGENETICS.COM;
follow @SOPHiAGENETICS on Twitter.
SOPHiA GENETICS Forward-Looking Statements:
This
press release contains statements that constitute forward-looking
statements. All statements other than statements of historical
facts contained in this press release, including statements
regarding our future results of operations and financial position,
business strategy, products and technology, as well as plans and
objectives of management for future operations, are forward-looking
statements. Forward-looking statements are based on our
management's beliefs and assumptions and on information currently
available to our management. Such statements are subject to risks
and uncertainties, and actual results may differ materially from
those expressed or implied in the forward-looking statements due to
various factors, including those described in our filings with the
U.S. Securities and Exchange Commission. No assurance can be given
that such future results will be achieved. Such forward-looking
statements contained in this document speak only as of the date of
this press release. We expressly disclaim any obligation or
undertaking to update these forward-looking statements contained in
this press release to reflect any change in our expectations or any
change in events, conditions, or circumstances on which such
statements are based, unless required to do so by applicable law.
No representations or warranties (expressed or implied) are made
about the accuracy of any such forward-looking statements.
Logo
- https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg